Study details
Enrolling now
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
NCT IDNCT04678648ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
134
Study length
about 5.9 years
Ages
18+
Locations
3 sites in CA, CO, TN
What this study is about
This trial is testing a treatment called RSC-1255 in adults with advanced cancers that haven't responded to other treatments. It has two phases: one to find the right dose and another to see if it works.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take RSC-1255 Dose Escalation
- 2.Take RSC-1255 Dose Expansion
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy
Secondary: Adverse event profile of RSC-1255, Overall Survival (OS)
Body systems
Oncology